PEAK6’s NewAmsterdam Pharma NAMS Stock Holding History

PEAK6’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,749	Closed	-$728K	–	3081
2025 Q4	$728K	Buy	+20,749	New	+$755K	﹤0.01%	1921

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

PEAK6's NAMS Position: Q1 2026 in Review

PEAK6 sold out of NewAmsterdam Pharma (NAMS) in Q1 2026, closing a stake of 20,749 shares — an estimated $728K sold.

PEAK6 first reported a position in NAMS in Q4 2025 and held it in 1 quarter. The position peaked at $728K in Q4 2025. 171 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

PEAK6 reported no remaining NewAmsterdam Pharma position as of Q1 2026 after selling out during the quarter.
PEAK6 sold 20,749 NewAmsterdam Pharma shares in Q1 2026, an estimated $728K.
PEAK6 first reported a position in NewAmsterdam Pharma in Q4 2025 and held it in 1 quarter.
PEAK6's NewAmsterdam Pharma position peaked at $728K in Q4 2025.
171 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on PEAK6's 13F filing for Q1 2026, filed 14 May 2026.